Company Filing History:
Years Active: 2021
Title: Nathan T Schomer: Innovator in Cellular Immunotherapy
Introduction
Nathan T Schomer is an accomplished inventor based in San Diego, California, with a focus on advancements in cellular immunotherapy. He holds three patents that showcase his dedication to improving therapeutic strategies for combating cancer. His latest innovations emphasize the importance of modified NK-92® cells in enhancing the efficacy of immunotherapies.
Latest Patents
Schomer's most recent patents include a significant invention involving a quadricistronic system. This system consists of a homing receptor and a chimeric antigen receptor (CAR) designed for stable genetic modification of cellular immunotherapies. Specifically, the patents describe modified NK-92® cells that incorporate nucleic acids encoding various components, including a homing receptor, an Antigen Binding Protein (ABP) or CAR, and an Fc Receptor such as CD16 or CD16-158V. Additionally, these cells may include sequences for cytokines, thereby enhancing their potential for targeted cancer treatment. The patents also cover methods, compositions, and kits that utilize these modified NK-92® cells for effective cancer therapies.
Career Highlights
Throughout his career, Nathan T Schomer has made substantial contributions to the field of immunotherapy. He has been associated with notable companies such as NantKwest Inc. and ImmunityBio, Inc., where he has collaborated with other experts in the field to advance cellular therapy technologies. Schomer's work is characterized by a clear vision of harnessing the immune system to fight malignancies more efficiently.
Collaborations
Nathan has worked alongside esteemed colleagues, such as Hans G. Klingemann and Laurent H. Boissel. These collaborations have played a vital role in pushing the boundaries of current cancer treatment methodologies, further showcasing Schomer's commitment to innovative research and development in immunotherapy.
Conclusion
In conclusion, Nathan T Schomer represents a significant force in the field of cellular immunotherapies, with a focus on the genetic modification of NK-92® cells. His innovative patents and collaborations reflect his dedication to advancing cancer treatment solutions. As he continues to explore the potential of immunotherapies, his contributions will undoubtedly have lasting impacts on the medical field.